AMENDMENTS TO THE CLAIMS:

The following is a complete listing of the claims and reflects all changes currently being made to the claims. This listing supersedes all earlier versions and all earlier listings of the claims.

1. (Currently Amended) A tablet capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising

a therapeutically effective amount of a pharmaceutically active ingredient contained in a matrix consisting essentially of

from about 15 to about 90% by weight of directly compressible dextrose monohydrate and

about 0.5 to about 5 % by weight of sucralose, the % weight being based on the total weight of said tablet, and

wherein said tablet has a weight ratio of dextrose monohydrate to sucralose of at least about 25:1, and

wherein said tablet is formed by direct compression and said tablet is fat-free and said matrix is substantially free of non-saccharide, water soluble polymeric binders.

- 2. (Original) The tablet of claim 1, wherein the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.
- 3. (Original) The tablet of claim 1, wherein the directly compressible dextrose monohydrate has an average particle size of about 100 to about 250 microns.

- 4. Cancelled.
- 5. (Original) The tablet of claim 1 containing about 25 to about 85 % by weight of dextrose monohydrate based on the total weight of the tablet.
 - 6. Cancelled.
 - 7. Cancelled.
 - 8. (Original) The tablet of claim 1 being substantially free of aspartame.
 - 9. (Original) The tablet of claim 1 wherein the pharmaceutically active ingredient has an average particle size from about 100 to about 500 microns.
 - 10. Cancelled.
 - 11. (Original) The tablet of claim 1 being substantially free of microcrystalline cellulose.
 - 12. (Currently Amended) A tablet capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising
 - a pharmaceutically active ingredient contained in a matrix comprising about 30 to about 75% by weight of directly compressible dextrose monohydrate;
 - about 0.5 to about 5 % by weight of sucralose based on the weight of the tablet;
 - at least one disintegrating agent selected from the group consisting of microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, and mixtures thereof;
 - at least one lubricant selected from the group consisting of magnesium stearate, stearic acid, and mixtures thereof; and

optionally an auxiliary ingredient selected from the group consisting of fillers, sweeteners, surfactants, glidants, acidulents, antioxidants, preservatives, coloring, flavoring agents, and mixtures thereof; wherein said tablet has a weight ratio of dextrose monohydrate to sucralose of at least about 25:1, and wherein said tablet is formed by direct compression and said tablet is substantially free of triglycerides and said matrix is substantially free of non-saccharide, water soluble polymeric binders.

- 13. (Previously Presented) The tablet of claim 12 wherein the tablet comprises no more than 25 % by weight of said optional auxiliary ingredients.
- 14. (New) The tablet of claim 1, wherein the tablet has a weight ratio of dextrose monohydrate to sucralose that is at least about 25:1.